Page last updated: 2024-10-24

candesartan and Ischemic Attack, Transient

candesartan has been researched along with Ischemic Attack, Transient in 4 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)

Research Excerpts

ExcerptRelevanceReference
"Treatment with candesartan, pioglitazone, and their combination resulted in significantly reduced mRNA expression of the inflammatory markers CXCL1 and TNFalpha in vivo (P<0."1.35Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. ( Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A, 2008)
"Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion."1.32The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. ( Doerfler, A; Engelhorn, T; Forsting, M; Goerike, S; Heusch, G; Okorn, C; Schulz, R, 2004)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukui, T1
Rahman, M1
Hayashi, K1
Takeda, K1
Higaki, J1
Sato, T1
Fukushima, M1
Sakamoto, J1
Morita, S1
Ogihara, T1
Fukiyama, K1
Fujishima, M1
Saruta, T1
Engelhorn, T2
Goerike, S1
Doerfler, A2
Okorn, C1
Forsting, M1
Heusch, G2
Schulz, R2
Schmerbach, K1
Schefe, JH1
Krikov, M1
Müller, S1
Villringer, A1
Kintscher, U1
Unger, T1
Thoene-Reineke, C1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463]Phase 33,200 participants Interventional2001-09-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for candesartan and Ischemic Attack, Transient

ArticleYear
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2003, Volume: 26, Issue:12

    Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio

2003

Other Studies

3 other studies available for candesartan and Ischemic Attack, Transient

ArticleYear
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2004, Volume: 24, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure

2004
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Neuroscience letters, 2006, Oct-02, Volume: 406, Issue:1-2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra

2006
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
    Brain research, 2008, May-07, Volume: 1208

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Benzimidazoles; Biph

2008